Background: Limited data exist regarding tenofovir disoproxil fumarate (TDF) safety and effectiveness in chronic hepatitis B virus-infected (CHB) patients with renal impairment (RI).
Aims: To compare real-world data on renal safety and effectiveness of TDF vs entecavir (ETV) in CHB patients with moderate-to-severe RI.
Methods: Retrospective, non-interventional, cohort study analysing medical records for TDF/ETV-treated CHB patients (54 European centres). Included patients experienced moderate-to-severe RI (creatinine clearance 20-60 mL/min [Cockcroft-Gault]) either before TDF/ETV initiation ('before' subgroup [baseline = treatment initiation]) or after TDF/ETV initiation ('after' subgroup [baseline = first RI occurrence]). The primary objective was TDF safety, particularly renal-related adverse events of special interest (AESI). TDF and ETV safety and effectiveness were compared and multivariate analyses were performed using inverse probability treatment weighting.
Results: 'Before' subgroup included 107 TDF- and 91 ETV-treated patients; 'after' subgroup included 212 TDF- and 77 ETV-treated patients. Mean baseline creatinine clearance was higher for TDF- vs ETV-treated patients (both subgroups). Median follow-up was 3.1 years (both treatments). AESI were more frequent with TDF vs ETV ('before': 18.7% vs 8.8%; 'after': 9.9% vs 3.9%); however, differences were not significant by multivariate analysis. Only TDF-treated patients experienced renal tubular dysfunction (6.5% 'before'; 1.9% 'after') as well as renal adverse events leading to treatment discontinuation (8.4% 'before'; 7.1% 'after'). Effectiveness was similar between treatments.
Conclusions: Overall safety was similar for TDF vs ETV (both subgroups). Given that renal tubular dysfunction occurred with TDF and not with ETV, renal safety concerns may be greater with TDF in CHB patients with RI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383725 | PMC |
| http://dx.doi.org/10.1111/apt.15901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Granulomatosis with polyangiitis with cardiac and large vessel involvement: a case report with a constellation of rare complications.
Eur Heart J Case Rep
January 2025
Department of Cardiology, Christian Medical College, New Arcot Road, Vellore 632517, India.
Background: Granulomatosis with polyangiitis (GPA) is an autoimmune multisystem disorder characterized by small vessel vasculitis with granulomatous inflammation. In this report, we describe a unique case of GPA who presented with complete heart block (CHB) and developed complications due to intracranial large vessel involvement.
Case Summary: A 47-year-old gentleman presented with CHB with a background history of arthralgia and blood-tinged nasal discharge.
[B cells in chronic hepatitis: advances and mechanistic].
Zhonghua Gan Zang Bing Za Zhi
December 2024
Senior Department of Infection Disease, the Fifth Medical Center of PLA General Hospital, Beijing100039, China.
The article reviews the role and functional diversity of B cells in chronic hepatitis B (CHB). B cells play a crucial role in humoral immunity, participating in the clearance of hepatitis B virus (HBV) through antibody production, antigen presentation, and immune regulation. In HBV infection, B cells exhibit antigenic heterogeneity, with immune responses to different HBV antigens varying.
View Article and Find Full Text PDF[The distributions of serum HBsAg level in chronic hepatitis B patients based on the China Registry of Hepatitis B (CR-HepB)].
Zhonghua Gan Zang Bing Za Zhi
December 2024
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center for Digestive Diseases, Beijing100050, China.
To determine the distributions of serum HBsAg level in treatment-naive or treatment-experienced chronic hepatitis B (CHB) patients. Based on the China Registry of Hepatitis B (CR-HepB), a nationwide hospital-based electronic platform, treatment-naive or treatment-experienced CHB patients who receive nucleos(t)ide analog (NA) therapy were enrolled in our study. We collected patients' clinical characteristics, including demographic, virological and biochemical data.
View Article and Find Full Text PDFUrinary Circular RNA Panels to Detect HBV-Related Hepatocellular Carcinoma: A Multicenter, Large-Scale, Case-Control Study.
J Natl Compr Canc Netw
December 2024
1Department of Hepatology, The Fifth People's Hospital of Ganzhou, Ganzhou, Jiangxi Province, China.
Purpose: More than 60% of patients with hepatocellular carcinoma (HCC) do not receive curative therapeutics due to late clinical manifestations and diagnosis. The 5-year survival rate for advanced HCC is approximately 2%. However, curative therapies for HCC detected early can improve the 5-year survival rate to >70%.
View Article and Find Full Text PDFLongitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters.
Clin Mol Hepatol
December 2024
Department of Medicine, Queen Mary Hospital, The University of Hong Kong.
Background: Plasma pregenomic hepatitis B virus RNA (pgRNA) is a novel biomarker in chronic hepatitis B infection (CHB). We aimed to describe the longitudinal profile of pgRNA and factors influencing its levels in CHB patients on nucleoside analogue (NUC).
Methods: Serial plasma samples from 1354 CHB patients started on first-line NUC were evaluated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!